- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00587990
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) (PROMETHEUS)
A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Intramyocardial Injection of Autologous Human Mesenchymal Stem Cells (MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction (MI) Undergoing Cardiac Surgery for Coronary Artery Bypass Grafting (CABG)
Обзор исследования
Статус
Подробное описание
Participation in this study will last 18 months. Potential participants will undergo initial screening 5 to 7 weeks prior to CABG surgery. Screening will include a physical exam, blood draw, pregnancy test, questions about medical history, current medications, and alcohol or drug use, an electrocardiogram (ECG), magnetic resonance imaging (MRI) of the heart, questionnaires, an echocardiogram and a computed tomography (CT) scan. Eligible participants will then undergo two baseline visits within 6 weeks of their scheduled surgery. Baseline Visit 1 will consist of vital sign measurements, a bone marrow aspiration to obtain MSCs and a blood draw for a biomarker test. Baseline Visit 2 will include treadmill test, 6-minute walk test, pulmonary function (FEV1) study and a 48 Hour Ambulatory ECG. After the second baseline visit, participants will be assigned randomly to receive either MSCs or placebo after surgery.
On the day of surgery, once all of the bypass grafts have been placed, a high or low dose of MSCs or placebo will be injected into a damaged area of the heart that did not receive a bypass graft. After receiving the injections, participants will remain in the hospital for up to 7 days. During this stay, participants will undergo a daily blood draw, urine test, ECG, and ambulatory ECG monitoring for the first 96 hours after surgery.
Upon being discharged, participants will return for monthly visits for 6 months and for follow-up visits 12 and 18 months after surgery. These visits will repeat most initial screening and baseline tests. There will be one additional visit 14 days after surgery, which will include questions about side effects, a physical exam, and a 48-hour ambulatory ECG.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Florida
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Miller School of Medicine
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21205
- Johns Hopkins University School of Medicine
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Diagnosis of chronic ischemic heart failure caused by a heart attack
- Scheduled to undergo cardiac surgery for CABG
- Ejection fraction between 15% and 50%
- Presence of an akinetic or dyskinetic region by standard imaging
Exclusion Criteria:
- Glomerular filtration rate of less than 50 mL/min/1.73m2 at study entry
- Contraindication to performance of an MRI scan
- Bone marrow dysfunction, as evidenced by a 20% or more deviation from normal hematocrit, white blood cell count, or platelet values without another explanation
- A coagulopathy condition not due to a reversible cause (i.e., Coumadin)
- Known, serious radiographic contrast allergy
- Known allergies to penicillin or streptomycin
- Organ transplant recipient
- Clinical history of malignancy within 5 years of study entry (e.g., patients with prior malignancy must be disease free for 5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma
- Non-cardiac condition that limits lifespan to less than 1 year
- On chronic therapy with immunosuppressant medication
- Serum positive for HIV, hepatitis B, or hepatitis C
- Female who is pregnant, nursing, or of child-bearing potential and not practicing effective birth control methods
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Lower dose mesenchymal stem cell (MSC) injection
Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
|
Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10^7 cells.
The injections will be administered following completion of CABG surgery.
|
Экспериментальный: Higher dose MSC injection
Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
|
Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10^8 cells.
The injections will be administered following completion of CABG surgery.
|
Плацебо Компаратор: (3) Placebo
Participants will receive placebo injections
|
Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Number of Patients With Serious Adverse Events
Временное ограничение: 12 Months
|
Six-month post-CABG surgery serious adverse event (SAE) proportion of patients experiencing a composite of sustained ventricular arrhythmias, (lasting longer than 15 seconds), with hemodynamic compromise, sudden unexpected death at six months, ectopic tissue formation at 12 months by chest/abdomen/pelvis CT exam.
|
12 Months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Change in Infarct Scar Size (ISS) Over 18 Month Period
Временное ограничение: Baseline, 6 Months, 18 Months
|
Change in infarct scar size (ISS) between baseline and 6-month and 18 month visits as determined by delayed contrast-enhanced MRI.
|
Baseline, 6 Months, 18 Months
|
Left Ventricular Function (LVF) in Region of MSC Injection
Временное ограничение: Assessed at Baseline and 18 Months
|
The Left Ventricular Function differences in the region of MSC injection were evaluated.
LVF is evaluated via ECHO as the percentage of ejected blood.
|
Assessed at Baseline and 18 Months
|
Regional Left Ventricular Wall Thickening
Временное ограничение: Assessed at Baseline and 18 months
|
Difference between baseline and 18 month regional left ventricular wall thickening as determined by MRI.
|
Assessed at Baseline and 18 months
|
Left Ventricular End Diastolic Wall Thickness
Временное ограничение: Assessed at Baseline and 18 months
|
Difference between the baseline and 18 month left ventricular end diastolic wall thickness as determined by MRI and echocardiogram.
|
Assessed at Baseline and 18 months
|
Change in Left Ventricular End Diastolic and Systolic Volume
Временное ограничение: Baseline, 6 Months, 18 Months
|
Change in left ventricular end diastolic and systolic volume as determined by MRI and echocardiogram.
|
Baseline, 6 Months, 18 Months
|
Change in Left Ventricular Ejection Fraction
Временное ограничение: Baseline to 6 Months, Baseline to 18 Months
|
Change between baseline to 6-month and 18-month left ventricular ejection fraction (LVEF) as determined by MRI and echocardiogram.
|
Baseline to 6 Months, Baseline to 18 Months
|
Change in Peak Volume Oxygen
Временное ограничение: Baseline, 6 Months, 18 Months
|
Change in Peak VO2 as determined by treadmill test (mL/mg/min) from Baseline to 6 and from baseline to 18 months
|
Baseline, 6 Months, 18 Months
|
Change in Six Minute Walk Test
Временное ограничение: Baseline, 6 Months, 18 Months
|
Change in Six Minute Walk Test (in meters) from Baseline to 6 Months and Baseline to 18 Months
|
Baseline, 6 Months, 18 Months
|
Change in NYHA Functional Class
Временное ограничение: Baseline to 6 Months, 6 months to 18 Months
|
Change in New York Heart Association (NYHA) Functional Classification based on patient's self reported activity level. Worsened: documented increase in limitations of physical activity as self-described by subject Improved: documented decrease in limitations of physical activity as self-described by subject Unchanged: no documented change in limitations of physical activity as self-described by subject |
Baseline to 6 Months, 6 months to 18 Months
|
Minnesota Living With Heart Failure Questionnaire Scores
Временное ограничение: Assessed at 6 Months and 18 Months
|
Minnesota Living with Heart Failure (MLHF) questionnaire has a total score from 0 to 105.
A higher score indicates that participants heart failure is preventing them from living their lives measured at two time points.
|
Assessed at 6 Months and 18 Months
|
Incidence of Major Adverse Cardiac Events (MACE)
Временное ограничение: 18 Months
|
Incidence of Major Adverse Cardiac Events (MACE).
A composite incidence of (1) death, (2) hospitalization for heart failure, or (3) non-fatal recurrent Ml.
|
18 Months
|
Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings
Временное ограничение: Assessed at 6 Months, 12 Months, and 18 Months
|
Ambulatory ECG monitoring is the most widely employed technology for the evaluation of a patient with symptoms suggestive of cardiac arrhythmia or conduction abnormality. When the patient returns for follow up the 48- Hour Ambulatory monitor provides the data to the site staff to detect any abnormal recordings based upon standard ECG protocol. |
Assessed at 6 Months, 12 Months, and 18 Months
|
Change in Pulmonary Function
Временное ограничение: Baseline, 6 Months, 12 Months, 18 Months
|
Change in Pulmonary Function from Baseline to 6 month, Baseline to 12 month, and Baseline to 18 month visits as measured by forced expiratory volume in 1 second (FEV1)
|
Baseline, 6 Months, 12 Months, 18 Months
|
Serial Troponin Values (ng/mL)
Временное ограничение: Assessed at Baseline, 12 hours, 24 hours, 36 hours, and 48 hours post CABG
|
Serial Troponin Values (ng/mL) Values from Baseline to 48 Hours Post CABG
|
Assessed at Baseline, 12 hours, 24 hours, 36 hours, and 48 hours post CABG
|
Creatinine Kinase - Muscle/Brain (MB) (ng/mL)
Временное ограничение: Assessed at Baseline, 12 Hours, 24 Hours, 36 Hours, and 48 hours post CABG
|
Creatinine Kinase MB (ng/mL) Values every 12 hours from Baseline to 48 Hours Post CABG
|
Assessed at Baseline, 12 Hours, 24 Hours, 36 Hours, and 48 hours post CABG
|
Number of Clinically Significant Laboratory Values
Временное ограничение: 18 Months
|
Clinically significant laboratory values are first determined via standard laboratory normal values from a CAP and CLIA certified Laboratory and then assessed by investigator based on specific patient conditions and disease state.
|
18 Months
|
Rate of Treatment Emergent Adverse Events
Временное ограничение: Assessed at 6 Months, 12 Months, and 18 Months
|
Rate of Treatment Emergent Adverse Events Post Coronary Artery Bypass Graft (CABG) at 6 Months, 12 Months, and 18 Months
|
Assessed at 6 Months, 12 Months, and 18 Months
|
Number of Abnormal Echocardiogram Readings 2 Days Post CABG.
Временное ограничение: Day 2
|
The number of abnormal Echocardiogram readings 2 Days Post CABG will be documented based on transthoracic Echocardiographic standards.
However, although Echocardiograms 2 days post CABG operation may show abnormalities which is standard in this population, this testing is instrumental because it measures End- diastolic wall thickness and Left ventricular volumes at end-diastole and end-systole.
|
Day 2
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Joshua M. Hare, MD, University of Miami
- Главный следователь: Gary Gerstenblith, MD, Johns Hopkins University
- Главный следователь: John V. Conte, MD, Johns Hopkins University
- Главный следователь: Steven P. Schulman, MD, Johns Hopkins University
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 20070598
- U54HL081028 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Трансплантация стволовых клеток
-
Rutgers, The State University of New JerseyЗавершенныйМБСР-STEM | ПМР-STEM | MBSR-НЕ-STEM | PMR-БЕЗ СТЕЛАСоединенные Штаты
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyПрекращеноПроизводство и банковское обслуживание iPS Cell
-
Shanghai General Hospital, Shanghai Jiao Tong University...РекрутингCAR-T Cell | Ph Положительный ВСЕ | ДазатинибКитай
-
China Medical University, ChinaЕще не набираютPD-1 антитело | Желудочно-кишечные опухоли | DC-ячейка | NK-Cell
-
Second Affiliated Hospital of Guangzhou Medical...Guangdong Zhaotai InVivo Biomedicine Co. Ltd.; Hunan Zhaotai Yongren Medical Innovation...РекрутингРак | Рак легких | Иммунотерапия | CAR-T CellКитай
-
Medical College of WisconsinUniversity of Wisconsin, Madison; AmgenРекрутингВ-клеточный острый лимфобластный лейкоз | B-клеточный острый лимфобластный лейкоз у детей | B-Cell ВСЕ, ДетствоСоединенные Штаты
-
ExelixisЗавершенныйКарцинома почек | Папиллярный рак щитовидной железы | Фолликулярный рак щитовидной железы | Рак щитовидной железы Huerthle CellСоединенные Штаты
-
University of Alabama at BirminghamПрекращеноАнапластическая крупноклеточная лимфома | Ангиоиммунобластная Т-клеточная лимфома | Периферические Т-клеточные лимфомы | Т-клеточный лейкоз взрослых | Т-клеточная лимфома взрослых | Периферическая Т-клеточная лимфома неуточненная | Системный тип T/Null Cell | Кожная Т-клеточная лимфома с узловым/висцеральным...Соединенные Штаты